A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBH

AstraZeneca closed FY/Q4 2025 with revenue of $58.7 billion, up 8.6% YoY, after-tax profit rising to $10.2 billion from $7.0 billion and oncology products comprising ~44% of Q4 product sales; the board declared a higher interim dividend and management flagged 20 Phase 3 readouts in 2026. Edwards Lifesciences reported Q4 sales growth of 13.3% YoY driven by TAVR/SAPIEN momentum but missed adjusted EPS expectations and saw gross margin slip 0.8% YoY while reaffirming 2026 guidance of +8–10% sales growth and EPS $2.90–3.05. Zimmer Biomet beat Q4 estimates with EPS $2.42 (+$0.04) and revenue $2.2 billion (+~11% YoY), issued conservative 2026 guidance (adj. EPS $8.30–8.45, FCF +8–10%) and warned tariffs could pressure results, leaving investors to weigh strong underlying demand against margin/headwind risks.

Analysis

Market structure: AstraZeneca's quarter reinforces durable pricing and market share in oncology (44% of Q4 product sales), concentrating revenue upside in a few high-margin assets; device makers Edwards (TAVR) and Zimmer (orthopedics) show demand elasticity tied to procedure volumes and reimbursement. Expect relative winners: diversified pharma (AZN) and TAVR leaders (EW); losers: exposure to tariffed manufacturing (ZBH) and smaller medtechs with less pricing power. Cross-asset: sustained pharma strength should modestly steepen sovereign curves (risk-on), compress corporate spreads in IG healthcare, and lift implied vols in device names ahead of device/regulatory catalysts.

Risk assessment: Key tail risks are Phase 3 failures at AZN (20 readouts in 2026), sudden Medicare reimbursement changes for TAVR/orthopedics, and tariff escalation hitting ZBH margins. Time buckets: immediate (days) — earnings repricing & vol spikes; short-term (weeks–months) — execution versus guidance and margin trends; long-term (quarters–years) — pipeline binary readouts and patent/exclusivity events. Hidden dependencies include concentrated oncology revenue (AZN) and hospital capital cycles driving device demand.

Trade implications: Favor asymmetric long exposure to AZN’s pipeline with limited premium (calendar or vertical call spreads) and tactical long EW equity with downside protection to capture TAVR adoption; avoid outright long ZBH because of tariff risk — use protective puts if holding. Pair trades: long EW / short ZBH to express TAVR outperformance vs tariff-exposed orthopedics. Options: buy 9–15 month AZN call spreads around key Phase 3 windows and buy 3–6 month protective puts on EW/ZBH if guidance weakens.

Contrarian angles: Consensus may underprice AZN’s pipeline optionality — a 50%+ implied downside in targets conflicts with 8–10% revenue growth guidance and 20 Phase 3 readouts; market may have over-rotated away from large-cap pharma into pure-play devices post-earnings. The EW EPS miss looks partially technical (mix, margin) not demand — a disciplined buy-if-margin stabilizes (≤200 bps further decline triggers reassessment). Unintended consequence: crowded long-AZN vs short-medtech positioning could suffer if a systemic rotation into defensive healthcare occurs on macro stress.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in AZN via a 12-month call spread (buy ATM call, sell 25% OTM call) to capture pipeline upside into 2026 Phase-3 readouts; target +25–35% in 6–12 months, place stop-loss/hedge if shares fall >12% or upcoming readout misses.
• Initiate a 1.5–2% long position in EW (ticker EW) using a protective-collar for 3–6 months: buy shares, buy 5% OTM puts and sell 15% OTM calls to finance downside protection; exit if gross margin contracts another ≥200 bps or management cuts FY2026 EPS guidance below $2.90.
• Avoid initiating new long exposure to ZBH; if already long, buy 6–9 month puts to cap downside until tariff clarity. Consider a relative-value pair: long EW (2%) / short ZBH (1%) to express TAVR secular growth vs tariff risk, rebalancing if spread narrows <5% on a market-cap weighted basis.
• Rotate 3–5% of small-cap medtech holdings into large-cap pharma/device leaders (AZN, EW) over next 30 days to reduce idiosyncratic recall/tariff risk; increase cash/IG duration by 1–2% if AZN pipeline readouts fail (as a defensive shift).